The Legal Status of Pay-for-Delay Agreements in EU Competition Law: Generics (Paroxetine)

Forthcoming in (2020) 57 Common Market Law Review

25 Pages Posted: 5 Nov 2020

See all articles by Pablo Ibáñez Colomo

Pablo Ibáñez Colomo

London School of Economics - Law Department

Date Written: September 16, 2020

Abstract

This case note presents the ruling of the Court of Justice in Generics (Paroxetine) and considers its implications for Articles 101 and 102 TFEU. It is submitted, first, that the approach to the assessment of pay-for-delay agreements enshrined in the judgment can effectively minimise the risk of Type I and Type II errors. Second, the Court does not depart from the long-standing principle whereby EU law does not question the existence of intellectual property rights, but only their exercise.

The judgment, together with Budapest Bank, has important implications for the assessment of restrictions by object under Article 101(1) TFEU. Generics (Paroxetine) confirms that the evaluation of the object of an agreement is a case-by-case, context-specific inquiry. In addition, it notes that the pro-competitive aspects of an agreement may, as factors pertaining to the relevant economic and legal context, be considered as part of the said evaluation. In the same vein (and as confirmed in Budapest Bank), the conditions of competition that would have prevailed absent the practice may also play a role.

As far as Article 102 TFEU is concerned, finally, the judgment confirms that anticompetitive effects within the meaning of that provision only exist where a practice has an impact that goes beyond the limitation of the freedom of action of individual undertakings. In this sense, it seems necessary to consider the cumulative effects of individual agreements by reference to the market as a whole. This approach is consistent with Post Danmark II and Intel, both of which signalled the importance of the coverage of the practice.

Keywords: Article 101 TFEU; Article 102 TFEU; restriction of competition by object; anticompetitive effects; intellectual property; patents; pharmaceuticals; pay-for-delay

JEL Classification: K21; L14; L24; L41; L42

Suggested Citation

Ibáñez Colomo, Pablo, The Legal Status of Pay-for-Delay Agreements in EU Competition Law: Generics (Paroxetine) (September 16, 2020). Forthcoming in (2020) 57 Common Market Law Review, Available at SSRN: https://ssrn.com/abstract=3693746 or http://dx.doi.org/10.2139/ssrn.3693746

Pablo Ibáñez Colomo (Contact Author)

London School of Economics - Law Department ( email )

Houghton Street
London WC2A 2AE, WC2A 2AE
United Kingdom

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
262
Abstract Views
638
rank
135,646
PlumX Metrics